{
    "root": "012ba27f-5410-4461-bc8a-72004ac311a6",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Danazol",
    "value": "20221001",
    "ingredients": [
        {
            "name": "DANAZOL",
            "code": "N29QWW3BUO"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        },
        {
            "name": "D&C YELLOW NO. 10 ALUMINUM LAKE",
            "code": "CQ3XH3DET6"
        },
        {
            "name": "FD&C BLUE NO. 1 ALUMINUM LAKE",
            "code": "J9EQA3S2JM"
        },
        {
            "name": "FD&C BLUE NO. 2--ALUMINUM LAKE",
            "code": "4AQJ3LG584"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "STEARIC ACID",
            "code": "4ELV7Z65AP"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "D&C RED NO. 28",
            "code": "767IP0Y5NH"
        }
    ],
    "indications": null,
    "contraindications": null,
    "warningsAndPrecautions": "Danazol capsules, USP are available as follows:\n                  \n                     \n                     \n                     \n                        \n                            50 mg:\n                           \n                            Yellow opaque cap/white opaque body capsule. Imprinted with black ink stylized barr 633. Available in bottles of 100 (NDC 0555-0633-02) capsules.\n                           \n                        \n                        \n                            100 mg:\n                           \n                            Yellow opaque cap/yellow clear body capsule. Imprinted with black ink stylized barr 634. Available in bottles of 100 (NDC 0555-0634-02) capsules.\n                           \n                        \n                        \n                            200 mg:\n                           \n                            Orange opaque cap/orange clear body capsule. Imprinted with black ink stylized barr 635. Available in bottles of 60 (NDC 0555-0635-09) and 100 (NDC 0555-0635-02) capsules.\n                           \n                        \n                     \n                  \n                  Store at 20° to 25° C (68° to 77° F) [See USP Controlled Room Temperature].\n                  Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).\n                  Keep this and all medications out of the reach of children.\n                     \n                  \n                  Manufactured For:\n                     Teva Pharmaceuticals\n                     Parsippany, NJ 07054\n                  Rev. D 10/2022",
    "adverseReactions": "Danazol should not be administered to patients with:\n                  \n                     Undiagnosed abnormal genital bleeding.\n                     Markedly impaired hepatic, renal, or cardiac function.\n                     Pregnancy. (See \n                           WARNINGS\n                        .)\n                     Breastfeeding.\n                     Porphyria - Danazol can induce ALA synthetase activity and hence porphyrin metabolism.\n                     Androgen-dependent tumor. \n                     Active thrombosis or thromboembolic disease and history of such events. \n                     Hypersensitivity to danazol."
}